Bioactive Sphingolipids in Cancer Biology and Therapy

This volume presents information on both the basic and clinical aspects of sphingolipid-metabolizing enzymes in various cancers. The volume also includes discussions of the innovative techniques and approaches for quantitative analysis and imaging that could significantly impact the general understanding of this topic, and the potential benefit of targeting sphingolipid enzymes to develop novel cancer therapeutics. As well, the volume includes a critical examination of the specific pathways and pathobiologies associated with the altered regulation of sphingolipid metabolism as a contributor to the development and/or maintenance of pathological conditions such as cancer.

Yusuf A. Hannun, MD, is Director, Stony Brook Cancer Center, Vice Dean, Cancer Medicine, and Professor, Biochemistry and Cell Biology, Stony Brook University. He is a renowned molecular biologist and physician-scientist investigating the molecular mechanisms of cancer, with an expertise in sphingolipids. Dr. Hannun is currently on the Editorial Board of several journals, including Biomedicine and Biotechnology, Frontiers in Membrane Physiology, and Biophysics, Chemistry and Physics of Lipids, and has received several honors, including the ASBMB Avanti Award in Lipids and ISI Highly Citied Researchers (in Biology and Biochemistry), and is Fellow, the American Association and Advancement of Science. He has published 448 scientific papers, which have received more than 34,100 citations.

Chiara Luberto, Ph.D., is Research Associate Professor of Physiology and Biophysics, Stony Brook University.

Cungui Mao, Ph.D., is Associate Professor of Medicine, Stony Brook University.

Lina Marie Obeid, M.D., is Professor of Medicine and Dean of Research, Stony Brook University.